We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

239 hedge funds and large institutions have $2.88B invested in Nektar Therapeutics in 2021 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 74 increasing their positions, 79 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 21

2% more funds holding

Funds holding: 235 → 239 (+4)

0.07% less ownership

Funds ownership: 6.22% → 6.15% (-0.07%)

5% less call options, than puts

Call options by funds: $11.1M | Put options by funds: $11.8M

6% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 79

15% less capital invested

Capital invested by funds: $3.39B → $2.88B (-$509M)

Holders
239
Holders Change
+4
Holders Change %
+1.7%
% of All Funds
4.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
74
Reduced
79
Closed
21
Calls
$11.1M
Puts
$11.8M
Net Calls
-$642K
Net Calls Change
-$1.34M

Top Buyers

1
CCM
Camber Capital Management
Massachusetts
+$27.7M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$12.1M
3
Millennium Management
Millennium Management
New York
+$8.64M
4
State Street
State Street
Massachusetts
+$6.81M
5
Two Sigma Investments
Two Sigma Investments
New York
+$5.57M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$36.6M
2
Ameriprise
Ameriprise
Minnesota
-$30.9M
3
First Trust Advisors
First Trust Advisors
Illinois
-$16.5M
4
BlackRock
BlackRock
New York
-$7.95M
5
PI
Putnam Investments
Massachusetts
-$7.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
51
Tekla Capital Management
Massachusetts
$3.1M – – –
Tudor Investment Corp
52
Tudor Investment Corp
Connecticut
$3.05M +$3.28M +11,857 New
CS
53
Credit Suisse
Switzerland
$2.98M -$667K -2,411 -17%
AF
54
Advisornet Financial
Minnesota
$2.93M +$755K +2,729 +32%
PP
55
PDT Partners
New York
$2.9M +$91.3K +330 +3%
ACM
56
ACT Capital Management
Pennsylvania
$2.77M +$2.98M +10,767 New
MOACM
57
Mutual of America Capital Management
New York
$2.73M -$70K -253 -2%
State of Tennessee, Department of Treasury
58
State of Tennessee, Department of Treasury
Tennessee
$2.57M – – –
Ensign Peak Advisors
59
Ensign Peak Advisors
Utah
$2.56M – – –
UBS Group
60
UBS Group
Switzerland
$2.47M +$1.03M +3,726 +64%
AB
61
Amalgamated Bank
New York
$2.45M +$2.23M +8,057 +557%
State of New Jersey Common Pension Fund D
62
State of New Jersey Common Pension Fund D
New Jersey
$2.35M +$382K +1,381 +18%
TPSF
63
Texas Permanent School Fund
Texas
$2.33M -$4.71K -17 -0.2%
Group One Trading
64
Group One Trading
Illinois
$2.3M -$221K -800 -8%
Bank of America
65
Bank of America
North Carolina
$2.25M +$341K +1,233 +16%
EGM
66
Engineers Gate Manager
New York
$2.21M +$1.85M +6,678 +346%
ACM
67
AlphaCrest Capital Management
New York
$2.1M +$2.04M +7,373 +960%
FCM
68
Frontier Capital Management
Massachusetts
$2.01M -$6.07M -21,937 -74%
Citadel Advisors
69
Citadel Advisors
Florida
$1.97M +$188K +681 +10%
SAM
70
Storebrand Asset Management
Norway
$1.97M – – –
Hudson Bay Capital Management
71
Hudson Bay Capital Management
Connecticut
$1.89M +$646K +2,333 +47%
Wolverine Trading
72
Wolverine Trading
Illinois
$1.78M +$240K +866 +15%
Ohio Public Employees Retirement System (OPERS)
73
Ohio Public Employees Retirement System (OPERS)
Ohio
$1.74M +$171K +618 +10%
VIA
74
Vident Investment Advisory
Georgia
$1.72M -$9.41K -34 -0.5%
E
75
Ergoteles
New York
$1.68M +$1.29M +4,669 +254%
1 2
3
4 5

NKTR Hedge Fund Activity: Q2 2021 in Review

239 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2021, worth a combined $2.88B — down 15% from $3.39B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new NKTR positions and 21 closed out — a net gain of 4 holders — while 74 added to existing stakes and 79 trimmed.

The largest buyer was Camber Capital Management, adding an estimated $27.7M. The largest seller was Fidelity Investments, cutting an estimated $36.6M.

  • 239 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2021, up from 235 in Q1 2021.
  • Funds reported $2.88B of Nektar Therapeutics stock for Q2 2021, down 15% quarter-over-quarter.
  • 25 funds opened new Nektar Therapeutics positions in Q2 2021 and 21 closed out, a net change of +4 holders.
  • The largest Nektar Therapeutics buyer in Q2 2021 was Camber Capital Management, an estimated $27.7M added.
  • The largest Nektar Therapeutics seller in Q2 2021 was Fidelity Investments, an estimated $36.6M sold.

Based on aggregated 13F filings for Q2 2021.